Cite
VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
MLA
Li, Yun, et al. “VSTM2L Contributes to Anoikis Resistance and Acts as a Novel Biomarker for Metastasis and Clinical Outcome in Ovarian Cancer.” Biochemical & Biophysical Research Communications, vol. 658, May 2023, pp. 107–15. EBSCOhost, https://doi.org/10.1016/j.bbrc.2023.03.073.
APA
Li, Y., Zhang, J., Cai, Y., Liu, H., Yang, W., Xu, Y., & Huang, M. (2023). VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer. Biochemical & Biophysical Research Communications, 658, 107–115. https://doi.org/10.1016/j.bbrc.2023.03.073
Chicago
Li, Yun, Jingjing Zhang, Ying Cai, Hua Liu, Wen Yang, Yingjie Xu, and Masha Huang. 2023. “VSTM2L Contributes to Anoikis Resistance and Acts as a Novel Biomarker for Metastasis and Clinical Outcome in Ovarian Cancer.” Biochemical & Biophysical Research Communications 658 (May): 107–15. doi:10.1016/j.bbrc.2023.03.073.